7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Eisai Co., Ltd., a Japanese pharmaceutical company headquartered in Tokyo, Japan, is set to roll out its novel, Leqembi, developed to treat Alzheimer's disease. The company is expected to give the first doses to 1,500 patients in China on the launch of this new medical product.
Growth Prediction After Leqembi's Release
According to Reuters, Eisai will also experience massive growth once the Leqembi officially hits the market. The new drug for Alzheimer's disease will first be available for Chinese patients later this year.
The pharma company's spokesperson explained that it anticipates growth to speed up even more in 2025 because the disease's diagnosis also changes. Moreover, the representative said that more suitable Alzheimer's blood tests will also be ready, and this will further help the company reach a more significant share of the Chinese market, where an estimated 17 million people were diagnosed with an early stage of Alzheimer's.
"China is one of the fastest-aging countries in the world and is one of the most important countries in the area of Alzheimer's disease for Eisai," Eisai's spokesman stated. "The potential growth for Leqembi in China is huge."
Price and Eligibility
Eisai plans to release Leqembi in China and sell it for 200,000 yuan or around $28,180 annually. The company said it has not yet decided if it will ask for government coverage and will only do so after assessing the demand in the private market. If Eisai pushes through, it will be included on China's National Reimbursement Drug List, and prices could be reduced.
To be eligible for treatment with Eisai's Leqembi, patients must undergo cognitive and genetic testing to determine whether they have a gene that increases the drug's adverse side effects.
They must also go through testing to see if they have abnormal levels of amyloid. Once the treatment begins, all patients will still undergo a series of MRI scans to detect any potential fatal swelling and bleeding in the brain.
Approval of LEQEMBI By the FDA
The FDA approved Eisai's Leqembi in July 2023 to treat Alzheimer's Disease. According to the press release, it is the first and only approved treatment that has been able to lessen the rate of the disease's progression. The drug can also slow down cognitive and functional decline in adult patients.
Photo by: Eisai Website
